IceCure Medical Ltd (ICCM) U.S. FD&A's MarketingAuthorizationforProSenseCryoablation Call

Core Points - IceCure Medical has received U.S. FDA marketing authorization for ProSense Cryoablation for the local treatment of low-risk breast cancer in women aged 70 and above when combined with Endocrine Therapy [3] Group 1 - The conference call was held to discuss the FDA's marketing authorization for ProSense Cryoablation [3] - Participants in the call included IceCure Medical's CEO Eyal Shamir and VP of Sales, North America, Shad Good [3] - The company believes that ProSense will be the only Cryoablation System approved in the U.S. for early-stage breast cancer in the foreseeable future [5]